Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Histone deacetetylases (HDACs) are a group of corepressors of transcriptional activators and their levels of expression are potentially dysregulated in prostate cancer. Certain inhibitors of histone deacetylases show anti-tumor activity in prostate cancer cell lines. Here, we systemically studied the expression of HDACs in human prostate cancer and the suppression of prostate cancer growth and invasion by HDAC inhibitor SAHA. HDAC1-5 showed increased expression using a combination of DNA microarray, in-situ hybridization, and immunohistochemistry in benign and malignant human prostate tissue as well as RT-PCR and Western blot analysis on various PCa cell lines. Importantly, HDAC inhibitor SAHA suppressed, in particular, prostate cancer cell growth and invasion determined using cell proliferation and Matrigel invasion assays. The findings of this study show that the expression of HDACs and their associated corepressors are increased in prostate cancer in humans and HDAC inhibitor SAHA could serve as a potential therapeutic agent in prostate cancer in addition to anti-androgens.

[1]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[2]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[3]  R. Kingston,et al.  Cooperation between Complexes that Regulate Chromatin Structure and Transcription , 2002, Cell.

[4]  J. Winnie,et al.  Invasion of v-FosFBR-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes , 2004, Oncogene.

[5]  Rakesh Kumar,et al.  Emerging roles of MTA family members in human cancers. , 2003, Seminars in oncology.

[6]  V. Reinke,et al.  Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. , 2005, Molecular cell.

[7]  Rudolf Fahlbusch,et al.  Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo , 2005, Journal of neurochemistry.

[8]  N. Bertos,et al.  Class II histone deacetylases: structure, function, and regulation. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[9]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Yin-Won Lee,et al.  Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. , 2004, Biochemical and biophysical research communications.

[11]  L. Ossowski,et al.  Activation of Rb and decline in androgen receptor protein precede retinoic acid–induced apoptosis in androgen‐dependent LNCaP cells and their androgen‐independent derivative , 1999, Journal of cellular physiology.

[12]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[13]  Zhengxin Wang,et al.  Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer , 2008, Proceedings of the National Academy of Sciences.

[14]  D. Neal,et al.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.

[15]  Tao Liu,et al.  Histone deacetylase inhibitors: multifunctional anticancer agents. , 2006, Cancer treatment reviews.

[16]  J. Qin,et al.  Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.

[17]  D. Coradini,et al.  Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But , 2004, Clinical Cancer Research.

[18]  Z. Culig Role of the androgen receptor axis in prostate cancer. , 2003, Urology.

[19]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[20]  J. Chiao,et al.  Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. , 2006, Carcinogenesis.

[21]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[22]  W. Gerald,et al.  Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. , 2008, The American journal of pathology.

[23]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[24]  M. Pincus,et al.  Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations , 2008, Oncogene.

[25]  Hee June Choi,et al.  Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes , 2005, Nature.

[26]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[27]  W. Isaacs,et al.  Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. , 2006, Experimental cell research.

[28]  Michael L. Blackburn,et al.  An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. , 2003, The Biochemical journal.

[29]  B. Aggarwal,et al.  Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation* , 2006, Journal of Biological Chemistry.

[30]  Chawnshang Chang,et al.  Androgen receptor corepressors: An overview , 2005, The Prostate.

[31]  L. Ossowski,et al.  Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. , 2001, Cancer research.

[32]  W. Gerald,et al.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. , 2005, Molecular endocrinology.

[33]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[34]  D. Budman,et al.  Unique induction of p21WAF1/CIP1expression by vinorelbine in androgen-independent prostate cancer cells , 2003, British Journal of Cancer.